FDA Approves AstraZeneca's Nexium for Children Aged One to 11
Posted on: Friday, 29 February 2008, 12:00 CST
AstraZeneca has said that the FDA has approved the use of Nexium in children ages one to 11 years old for the short-term treatment of gastroesophageal reflux disease or GERD for up to eight weeks.
The FDA has also approved a new 10mg dose formulation of Nexium for delayed-release oral suspension for use in children one to 11 years old and the product will be available later this year.
Marta Illueca, Nexium brand medical director, AstraZeneca Pharmaceuticals US, said: "This dosing alternative of Nexium for oral suspension allows patients, such as children and the elderly, who are unable to swallow capsules or tablets to have an alternative treatment option for controlling their GERD."
Source: Datamonitor
Related Articles
- AstraZeneca Submits sNDA for NEXIUM(R) for the Short-Term Treatment of GERD in Infants 0 to 1 Year Old
- FDA Approves NEXIUM(R) for the Treatment of Short-Term GERD in Children 1 to 11 Years Old
- FDA OK's Nexium for New Use
- FDA Approves NEXIUM for the Treatment of Zollinger-Ellison Syndrome
- AstraZeneca's Nexium Approved for US Teenagers
- FDA Approves Use of NEXIUM(R) in Children Ages 12 to 17 For Short-Term Treatment of GERD
- After-School Multifamily Groups: A Randomized Controlled Trial Involving Low-Income, Urban, Latino Children
- Technology in Developing Countries: Creating Awareness in Children
- 1 in 4 Harlem Children Has Asthma
 |
 |
User Comments (0)
RSS Feeds